Trial Profile
High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2017
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary)
- Indications Adenocarcinoma; Brain metastases; Lung cancer
- Focus Therapeutic Use
- 01 Aug 2017 Status changed from not yet recruiting to recruiting as per the results published in the Anticancer Research.
- 01 Aug 2017 Results (n=60; data cut off Oct 2015) assessing efficacy and safety published in the Anticancer Research.
- 11 Nov 2014 New trial record